An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (SHIELD-4)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01536418
First received: February 16, 2012
Last updated: March 6, 2014
Last verified: February 2014
  Purpose

This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn's disease. Subjects will receive one of two doses (500 milligrams once daily, 500 milligrams twice daily) of GSK1605786A for 12 weeks. The primary objective of the study is to induce clinical response (Crohn's Disease Activity Index [CDAI] decrease from baseline of at least 100 points) and/or remission (CDAI score less than 150) with GSK1605786A at Week 12 in subjects with active Crohn's disease to qualify subjects for enrolment into a 52 week maintenance study (CCX114157). Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission. Safety will be assessed by recording of adverse events and assessment of changes in clinical laboratory parameters, vital signs and electrocardiogram. Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire, SF-36, EQ-5D, and Work Productivity and Activity Impairment-Crohn's Disease.


Condition Intervention Phase
Crohn's Disease
Drug: GSK1605786A
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Proportion of subjects achieving clinical response at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Subjects achieving clinical response defined by a CDAI decrease from baseline of at least 100 points at Week 12


Secondary Outcome Measures:
  • Proportion of subjects in clinical remission at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Subjects in clinical remission defined as a CDAI score of less than 150 points at Week 12

  • Proportion of subjects with clinical response at both Week 8 and Week 12 [ Time Frame: Both Week 8 and Week 12 ] [ Designated as safety issue: No ]
    Subjects with clinical response at both Week 8 and Week 12

  • Proportion of subjects with clinical remission at both Week 8 and Week 12 [ Time Frame: Both Week 8 and Week 12 ] [ Designated as safety issue: No ]
    Subjects with clinical remission at both Week 8 and Week 12

  • Proportion of subjects with clinical response at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
    Subjects with clinical response at Week 8

  • C-reactive protein concentration [ Time Frame: Weeks 4, 8 and 12 ] [ Designated as safety issue: No ]
    Change from baseline in C-reactive protein concentration at Weeks 4, 8 and 12

  • Faecal calprotectin [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Change from baseline in faecal calprotectin at Week 12


Enrollment: 255
Study Start Date: November 2011
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK1605786A, 500 milligrams, once daily
500 milligrams once daily, orally administered for 12 weeks
Drug: GSK1605786A
500 milligrams once daily, orally administered for 12 weeks
Experimental: GSK1605786A, 500 milligrams twice daily
500 milligrams twice daily, orally administered for 12 weeks
Drug: GSK1605786A
500 milligrams twice daily, orally adminstered for 12 weeks

Detailed Description:

This is a multi-centre, double-blind, randomised, active treatment, parallel group study designed to induce clinical response and/or clinical remission with two oral doses of GSK1605786A (500 milligrams once daily, 500 milligrams twice daily) over a 12-week treatment period in subjects with moderately-to-severely active Crohn's disease. The primary objective of this study is to qualify subjects for enrolment into a follow up 52 week maintenance study CCX114157. Subjects who achieve induction of clinical response (CDAI decrease from baseline of at least 100 points) or remission (CDAI score less than 150) at Week 12 following treatment with GSK1605786A will be eligible for enrolment into the maintenance study CCX114157. Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission.

The study is planned to randomise approximately 900 subjects (450 subjects per group) with active Crohn's disease who have been diagnosed for at least 4 months, with documented history of disease in the small and/or large intestine, and characterised by a CDAI score between 220 to 450 (inclusive). Subjects will be required to have evidence of current active inflammation by elevated C-reactive protein (greater than the upper limit of normal of the highly sensitive C-reactive protein test) OR an elevated level of faecal calprotectin. Subjects will be allowed to participate in the study while continuing on stable doses of agents typically used to treat Crohn's disease. Inclusion of subjects who received prior treatment with an anti-tumor necrosis factor agent and discontinued due to loss or lack of efficacy will be limited to approximately 50 percent of the study population. Following a 3-week screening period, subjects will be randomised at baseline to receive blinded treatment with one of two doses of GSK1605786A (500 milligrams once daily or twice daily) for 12 weeks. All subjects meeting the definition of responder (CDAI decrease from baseline of at least 100 points) or who are in remission (CDAI score less than 150 points) at Week 12 will be eligible for randomisation into an ongoing maintenance study (CCX114157). Subjects who do not meet the definition of responder or who are not in remission at Week 12 will not be eligible to participate in study CCX114157.

For subjects who complete the study the minimum duration of participation is 15 weeks and the maximum duration is 19 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged 18 years or older
  • Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications
  • Diagnosis of Crohn's disease for more than 4 months with small bowel and/or colonic involvement
  • Current evidence of moderately-to-severely active disease defined by a baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450, inclusive
  • Confirmation of active disease by elevated CRP (greater than or equal to the upper limit of normal for the highly sensitive C-reactive protein test) or elevated levels of faecal calprotectin
  • History of inadequate response and/or intolerance or adverse event leading to discontinuation of at least one of the following treatments for Crohn's disease: corticosteroids or immunosuppressants
  • Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease
  • Demonstrated ability to comply with Crohn's disease symptom recording using the interactive voice response system
  • Female subjects of child-bearing potential are eligible if not pregnant or nursing and committed to use of contraceptive methods with a failure rate of less than 1 percent per year

Exclusion Criteria:

  • Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for coeliac disease (elevated anti-tissue transglutaminase antibodies)
  • Diagnosis of ulcerative or indeterminate colitis
  • Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period
  • Bowel surgery, other than appendectomy, within 12 weeks prior to screening and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period
  • Extensive colonic resection, subtotal or total colectomy
  • Presence of ileostomies, colostomies or rectal pouches
  • Fixed symptomatic stenoses of small bowel or colon
  • History of more than 3 small bowel resections or diagnosis of short bowel syndrome
  • Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medicaitons
  • Use of prohibited medications, including enteral feeding or elemental diet, within their specified timeframes and throughout the study. Prohibited medications include the following:

    1. Biologic use: Use of any TNF inhibitor (such as infliximab, adalimumab or certolizumab) or natalizumab within 10 weeks prior to Randomisation
    2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to Screening
    3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to Screening
    4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease within 4 weeks prior to Screening
    5. Enteral feeding: Use of tube or enteral feeding, elemental diet within 2 weeks prior to Screening
    6. Rectal Treatment: Use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks prior to Screening
    7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening
    8. Paracetamol or acetaminophen greater than 2 grams per day
    9. Opioid analgesics for worsening Crohn's disease pain are prohibited when used on a regular daily basis for more than 3 days
    10. Digoxin or related cardiac glycosides: Use within 7 days prior to Screening
    11. Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B)
  • Positive immunoassay for Clostridium difficile
  • Known HIV infection
  • Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening
  • Immunization with a live vaccine within 4 weeks of Screening and throughout the study with the exception of the influenza vaccine
  • Positive hepatitis B surface antigen or hepatitis B core antibody test or positive Hepatitis C test result at Screening
  • Active or latent tuberculosis infection determined by results of QuantiFERON TB Gold test
  • Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks
  • Previous infections characterised by opportunistic pathogens, and/or dissemination suggestive of clinically significant immunocompromise
  • Evidence of hepatic dysfunction, viral hepatitis, or abnormalities in liver function test results
  • Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds
  • Congenital or acquired immunodeficiency or has evidence of immunocompromise manifested by current opportunistic infection
  • Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected)
  • History of evidence of adenomatous colonic polyps that have not been removed.
  • History of evidence of colonic mucosal dysplasia
  • If female, is pregnant, has a positive pregnancy test or is breast-feeding
  • Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (such as an unstable cardiovascular, autoimmune, renal, hepatic, pulmonary, endocrine, metabolic, gastrointestinal, haematologic, or neurological condition or mental impairment)
  • Medical history of sensitivity to any of the components of GSK1605786A (microcrystalline cellulose, crospovidone, sodium stearyl fumarate).
  • Use of any investigational product within 30 days prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01536418

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Little Rock, Arizona, United States, 72205
GSK Investigational Site
Tucson, Arizona, United States, 85712
United States, California
GSK Investigational Site
La Jolla, California, United States, 92037
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
GSK Investigational Site
Denver, Colorado, United States, 80222
GSK Investigational Site
Littleton, Colorado, United States, 80120
United States, Connecticut
GSK Investigational Site
Hamden, Connecticut, United States, 06518
GSK Investigational Site
New Haven, Connecticut, United States, 06510
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20007
United States, Florida
GSK Investigational Site
Jacksonville, Florida, United States, 32256-6004
GSK Investigational Site
Port Orange, Florida, United States, 32127
United States, Georgia
GSK Investigational Site
Suwanee, Georgia, United States, 30024
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60637
United States, Maryland
GSK Investigational Site
Chevy Chase, Maryland, United States, 20815
GSK Investigational Site
South Towson, Maryland, United States, 21286
GSK Investigational Site
Towson, Maryland, United States, 21204
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02114
United States, Michigan
GSK Investigational Site
Chesterfield, Michigan, United States, 48047
United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
United States, Missouri
GSK Investigational Site
Lee's Summit, Missouri, United States, 64064
GSK Investigational Site
Mexico, Missouri, United States, 65265-3726
United States, New York
GSK Investigational Site
Brooklyn, New York, United States, 11206
GSK Investigational Site
Lake Success, New York, United States, 11042
GSK Investigational Site
Stony Brook, New York, United States, 11794
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
GSK Investigational Site
Charlotte, North Carolina, United States, 28209
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43215
United States, Oklahoma
GSK Investigational Site
Tulsa, Oklahoma, United States, 74135
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97225
United States, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78745
United States, Utah
GSK Investigational Site
Ogden, Utah, United States, 84405
United States, Virginia
GSK Investigational Site
Christiansburg, Virginia, United States, 24073
GSK Investigational Site
Danville, Virginia, United States, 24541
GSK Investigational Site
Norfolk, Virginia, United States, 23502
GSK Investigational Site
Richmond, Virginia, United States, 23249
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53792
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Australia, New South Wales
GSK Investigational Site
Bankstown, New South Wales, Australia, 2200
Australia, Queensland
GSK Investigational Site
Hersten, Queensland, Australia, 4029
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
GSK Investigational Site
Box Hill, Victoria, Australia, 3128
GSK Investigational Site
Fitzroy, Victoria, Australia, 3065
GSK Investigational Site
Prahran, Victoria, Australia, 3181
Australia, Western Australia
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
Austria
GSK Investigational Site
Hall in Tirol, Austria, 6060
GSK Investigational Site
Linz, Austria, A-4021
GSK Investigational Site
Oberpullendorf, Austria, 7350
GSK Investigational Site
St.Veit/Glan, Austria, 9300
GSK Investigational Site
Wien, Austria, 1050
GSK Investigational Site
Wien, Austria, 1090
GSK Investigational Site
Wien, Austria, 1030
Belgium
GSK Investigational Site
Bonheiden, Belgium, 2820
GSK Investigational Site
Edegem, Belgium, 2650
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Kortrijk, Belgium, 8500
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Roeselare, Belgium, 8800
Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria, 4002
GSK Investigational Site
Sofia, Bulgaria, 1431
GSK Investigational Site
Sofia, Bulgaria, 1407
GSK Investigational Site
Sofia, Bulgaria, 1527
GSK Investigational Site
Varna, Bulgaria, 9010
Canada, Ontario
GSK Investigational Site
Kingston, Ontario, Canada, K7L 5G2
GSK Investigational Site
London, Ontario, Canada, N6A 5A5
GSK Investigational Site
London, Ontario, Canada, N6A 5W9
Chile
GSK Investigational Site
Vina del Mar, Chile, 2520012
Czech Republic
GSK Investigational Site
Hradec Králové, Czech Republic, 500 12
GSK Investigational Site
Olomouc, Czech Republic, 77520
GSK Investigational Site
Praha 4, Czech Republic, 140 59
GSK Investigational Site
Praha 9, Czech Republic, 190 00
GSK Investigational Site
Teplice, Czech Republic, 415 29
GSK Investigational Site
Usti nad Orlici, Czech Republic, 562 18
Denmark
GSK Investigational Site
Aalborg, Denmark, 9000
GSK Investigational Site
Aarhus, Denmark, 8000
GSK Investigational Site
Herlev, Denmark, 2730
GSK Investigational Site
Koebenhavn NV, Denmark, 2400
Estonia
GSK Investigational Site
Tallinn, Estonia, EE-10138
GSK Investigational Site
Tallinn, Estonia, 10617
GSK Investigational Site
Tartu, Estonia, 51014
France
GSK Investigational Site
Clichy cedex, France, 92118
GSK Investigational Site
Lille cedex, France, 59037
GSK Investigational Site
Paris cedex 10, France, 75475
GSK Investigational Site
Saint-Priest en Jarez, France, 42270
Germany
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89081
GSK Investigational Site
Weiden, Bayern, Germany, 92637
GSK Investigational Site
Frankfurt am Main, Hessen, Germany, 60590
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18057
GSK Investigational Site
Brinkum/Stuhr, Niedersachsen, Germany, 28816
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50937
GSK Investigational Site
Minden, Nordrhein-Westfalen, Germany, 32423
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06120
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39120
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Jena, Thueringen, Germany, 07747
GSK Investigational Site
Berlin, Germany, 10117
GSK Investigational Site
Hamburg, Germany, 20148
Greece
GSK Investigational Site
Athens, Greece, 11522
GSK Investigational Site
Athens, Greece, 10676
GSK Investigational Site
Athens, Greece, 18454
GSK Investigational Site
Heraklion, Crete, Greece, 71110
GSK Investigational Site
Ioannina, Greece, 45110
Hong Kong
GSK Investigational Site
Hong Kong, Hong Kong
GSK Investigational Site
Shatin, New Territories, Hong Kong
Hungary
GSK Investigational Site
Bekescsaba, Hungary, 5600
GSK Investigational Site
Budapest, Hungary, 1088
GSK Investigational Site
Budapest, Hungary, 1083
GSK Investigational Site
Budapest, Hungary, 1062
GSK Investigational Site
Budapest, Hungary, 1136
GSK Investigational Site
Debrecen, Hungary, 4025
GSK Investigational Site
Mosonmagyaróvár, Hungary, 9200
GSK Investigational Site
Szekszárd, Hungary, 7100
GSK Investigational Site
Vác, Hungary, 2600
Israel
GSK Investigational Site
Afula, Israel, 18101
GSK Investigational Site
Beer Sheva, Israel, 84101
GSK Investigational Site
Haifa, Israel, 31096
GSK Investigational Site
Holon, Israel, 58100
GSK Investigational Site
Jerusalem, Israel, 91031
GSK Investigational Site
Jerusalem, Israel, 91120
GSK Investigational Site
Kfar Saba, Israel, 44281
GSK Investigational Site
Petah Tikva, Israel, 49100
GSK Investigational Site
Ramat-Gan, Israel, 52621
GSK Investigational Site
Tel Aviv, Israel, 64239
GSK Investigational Site
Zerifin, Israel, 70300
Italy
GSK Investigational Site
Genova, Italy, 16132
Japan
GSK Investigational Site
Aichi, Japan, 460-0012
GSK Investigational Site
Aichi, Japan, 470-1219
GSK Investigational Site
Aichi, Japan, 441-8570
GSK Investigational Site
Fukuoka, Japan, 818-8502
GSK Investigational Site
Fukuoka, Japan, 802-0077
GSK Investigational Site
Fukuoka, Japan, 830-0011
GSK Investigational Site
Hiroshima, Japan, 720-8520
GSK Investigational Site
Hokkaido, Japan, 065-0033
GSK Investigational Site
Hyogo, Japan, 663-8501
GSK Investigational Site
Kagoshima, Japan, 892-0846
GSK Investigational Site
Kanagawa, Japan, 247-0056
GSK Investigational Site
Kanagawa, Japan, 220-0045
GSK Investigational Site
Osaka, Japan, 530-0011
GSK Investigational Site
Shizuoka, Japan, 430-0846
GSK Investigational Site
Tokyo, Japan, 169-0073
GSK Investigational Site
Wakayama, Japan, 641-8510
Korea, Republic of
GSK Investigational Site
Daegu, Korea, Republic of, 705-717
GSK Investigational Site
Pusan, Korea, Republic of, 602-739
GSK Investigational Site
Seoul, Korea, Republic of, 130702
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 135-230
GSK Investigational Site
Seoul, Korea, Republic of, 138-736
GSK Investigational Site
Wonju, Korea, Republic of, 220701
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
GSK Investigational Site
Amsterdam, Netherlands, 1091 AC
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
GSK Investigational Site
EDE, Netherlands, 6716 RP
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Rotterdam, Netherlands, 3083 AN
New Zealand
GSK Investigational Site
Canterbury, New Zealand, 8011
GSK Investigational Site
Dunedin, New Zealand, 9054
GSK Investigational Site
Hamilton, New Zealand, 3204
GSK Investigational Site
Lower Hutt, New Zealand, 6007
GSK Investigational Site
Otahuhu, New Zealand, 1640
GSK Investigational Site
Takapuna, Auckland, New Zealand, 1309
GSK Investigational Site
Tauranga., New Zealand, 3143
Poland
GSK Investigational Site
Bydgoszcz, Poland, 85-168
GSK Investigational Site
Bydgoszcz, Poland, 85-681
GSK Investigational Site
Lublin, Poland, 20-607
GSK Investigational Site
Sopot, Poland, 81-756
GSK Investigational Site
Wroclaw, Poland, 53-333
Portugal
GSK Investigational Site
Lisboa, Portugal, 1649-035
GSK Investigational Site
Lisboa, Portugal, 1769-001
GSK Investigational Site
Porto, Portugal, 4099-001
GSK Investigational Site
Viseu, Portugal, 3504-509
Russian Federation
GSK Investigational Site
Irkutsk, Russian Federation, 664079
GSK Investigational Site
Kazan, Russian Federation, 420064
GSK Investigational Site
Lipetsk, Russian Federation, 398055
GSK Investigational Site
Moscow, Russian Federation, 129110
GSK Investigational Site
Nizhniy Novgorod, Russian Federation, 603126
GSK Investigational Site
Rostov-on-Don, Russian Federation, 344091
GSK Investigational Site
Samara, Russian Federation, 443011
GSK Investigational Site
St. Petersburg, Russian Federation, 196247
GSK Investigational Site
St.Petersburg, Russian Federation, 197110
GSK Investigational Site
Tomsk, Russian Federation, 634063
Slovakia
GSK Investigational Site
Bratislava, Slovakia, 851 07
GSK Investigational Site
Bratislava, Slovakia, 851 01
GSK Investigational Site
Bratislava, Slovakia, 831 04
GSK Investigational Site
Nitra, Slovakia, 949 01
GSK Investigational Site
Nove Mesto nad Vahom, Slovakia, 915 01
GSK Investigational Site
Presov, Slovakia, 080 01
GSK Investigational Site
Trnava, Slovakia, 917 02
Spain
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Elche, Spain, 03293
GSK Investigational Site
Fuenlabrada (Madrid), Spain, 28942
GSK Investigational Site
Galdakao/Vizcaya, Spain, 48960
GSK Investigational Site
Madrid, Spain, 28006
GSK Investigational Site
Madrid, Spain, 28007
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Marbella, Spain, 29600
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
GSK Investigational Site
Santander, Spain, 39008
Switzerland
GSK Investigational Site
Bern, Switzerland, 3004
GSK Investigational Site
Zürich, Switzerland, 8091
Taiwan
GSK Investigational Site
Taichung, Taiwan, 40705
GSK Investigational Site
Taipei, Taiwan, 100
GSK Investigational Site
Taipei, Taiwan, 104
GSK Investigational Site
Taoyuan, Taiwan, 333
Turkey
GSK Investigational Site
Ankara, Turkey, 06100
Ukraine
GSK Investigational Site
Chernivtsi, Ukraine, 58005
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49044
GSK Investigational Site
Donetsk, Ukraine, 83099
GSK Investigational Site
Donetsk, Ukraine, 83017
GSK Investigational Site
Kharkiv, Ukraine, 61037
GSK Investigational Site
Kyiv, Ukraine
GSK Investigational Site
Odesa, Ukraine, 65117
GSK Investigational Site
Simferopol, Ukraine, 95017
GSK Investigational Site
Vinnytsya, Ukraine, 21029
United Kingdom
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom, G4 0SF
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
GSK Investigational Site
Birmingham, United Kingdom, B9 5SS
GSK Investigational Site
Dundee, United Kingdom, DD1 9SY
GSK Investigational Site
Edinburgh, United Kingdom, EH4 2XU
GSK Investigational Site
London, United Kingdom, E1 2AT
GSK Investigational Site
Manchester, United Kingdom, M13 9WL
GSK Investigational Site
Newcastle Upon Tyne, United Kingdom, NE1 4LP
GSK Investigational Site
Oxford, United Kingdom, OX3 9DU
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01536418     History of Changes
Other Study ID Numbers: 114643
Study First Received: February 16, 2012
Last Updated: March 6, 2014
Health Authority: Spain: Agencia Espanola de Medicamentos y Productos Sanitarios
Estonia: State Agency of Medicines
Greece: National Organization of Medicines
China: Food and Drug Administration
Russia: Federal Service of Surveillance in Healthcare and Social development of Russian federation
United States: Food and Drug Administration
Chile: SFDA -State Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Hong Kong: Department of Health
Austria: Austrian Medicines and Medical Devices Agency (AGES PharmMed)
Brazil: ANVISA - Agência Nacional de Vigilância Sanitaria
Portugal: Ministério da Saude (Ana Jorge)
South Korea: Food and Drug Administration
Europe: European Medicines Agency

Keywords provided by GlaxoSmithKline:
Crohn's disease, chemokine receptor 9 antagonist, Crohn's Disease Activity Index
active treatment

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on July 26, 2014